Evidence map›Paper›PMID 26242461›Full record

Trial reportLeukemia2016

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

S Ferrero, A Pastore, C W Scholz, R Forstpointner, A Pezzutto, L Bergmann, L Trümper, J Finke, U Keller, P Ghione and 5 more

Open access · greenAbstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

S FerreroDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
A PastoreDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
C W ScholzDepartment of Oncology and Hematology, Vivantes Klinikum, Berlin, Germany.
R ForstpointnerDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
A PezzuttoCharité University Medicine, Department of Hematology and Oncology, Berlin, Germany.
L BergmannMedical Clinic II, University Hospital, Frankfurt, Germany.
L TrümperDepartment of Hematology and Oncology, Georg-August Universiität, Göttingen, Germany.
J FinkeHematology/Oncology, University Medical Center, Freiburg, Germany.
U KellerIII Medical Department, Technische Universität München, Munich, Germany.
P GhioneDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
R PasseraBiostatistician, Division of Nuclear Medicine, Città della Salute e della Scienza, University of Torino, Torino, Italy.
W HiddemannDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
O WeigertDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
M UnterhaltDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
M DreylingDepartment of Medicine III, University Hospital Großhadern/LMU, München, Germany.
Ludwig-Maximilians-Universität München · DEUniversity of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCharité - Universitätsmedizin Berlin · DEGoethe University Frankfurt · DELMU Klinikum · DETechnical University of Munich · DEUniversity Medical Center Freiburg · DEUniversity of Göttingen · DEVivantes Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmRadioimmunotherapyAgedAged, 80 and overAntibodies, MonoclonalEuropeFemaleFollow-Up StudiesHumansLymphoma, Mantle-CellMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProspective StudiesAntibodies, Monoclonalibritumomab tiuxetanYttrium Radioisotopes

Identifiers

PMID26242461
OpenAlexW1863085061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.